



Dupixent in India

The CDSCO personal-import / named-patient coordination pathway — indicative 2026

IMMUNOLOGY · TYPE-2 INFLAMMATION IL-4RA

The clinical situation

Dupixent (dupilumab) is an FDA-approved human monoclonal antibody against IL-4 receptor alpha that blocks the shared IL-4 and IL-13 signalling axis, with indications spanning atopic dermatitis, severe asthma, eosinophilic oesophagitis, prurigo nodularis, and chronic spontaneous urticaria. Developed by Regeneron and Sanofi. Local registration and distribution in India vary by indication and by city; where a specific indication, age band, or supply need is not met locally, a named-patient / personal-import pathway may be appropriate. Administration is subcutaneous, with a loading dose followed by every-two-weeks or every-four-weeks maintenance depending on indication, age, and weight.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist, pulmonologist, allergist, or gastroenterologist documents diagnosis, age/weight, prior therapy, and the reason local supply does not meet the need.
- 2 CDSCO personal-import / named-patient application.** Physician or importing pharmacy files the dossier: Indian licence verification, patient reference, dosing plan, chain-of-custody.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under documented chain of custody.
- 4 Cold-chain shipment & arrival.** Temperature-controlled transport; the importer of record receives and hands off per your physician's protocol.
- 5 Initiation & re-supply cadence.** Most patients or caregivers self-inject at home after training; Reserve Meds supports the q2w / q4w maintenance cadence.

Indicative economics

Reference US cash-pay range: USD 3,500–4,000 per month at typical adult dosing (paediatric weight-banded dosing often lower; Reserve Meds issues a transparent delivered quote at intake and provides a total-cost-delivered comparison at intake).

Indicative first-shipment timing

10–21 days from a complete CDSCO application to first shipment, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Physician documentation kit keyed to CDSCO review. **Logistics.** Cold-chain shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and specialist team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Dupixent × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/dupixent-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team